In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
2018 · Nature Communications · 55 citations
https://doi.org/10.1038/s41467-018-05742-z
A
Albert Gris‐Oliver
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
96
Papers
1.4K
Citations
14
h-index
15
i10-index
Albert Gris‐Oliver is an academic researcher from Departament de Salut. The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Colorectal Cancer Treatments and Studies & Histone Deacetylase Inhibitors Research. The author has an h-index of 14, co-authored 82 publications.
ORCID: 0000-0003-1802-9541Papers by this author
worksAKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
2022 · Oncogene · 30 citations
https://doi.org/10.1038/s41388-022-02482-9
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
2021 · British Journal of Cancer · 18 citations
https://doi.org/10.1038/s41416-021-01293-1
Additional file 1 of Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12935530
Additional file 2 of Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12935533
FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma
2024 · Journal of Hepatology · 0 citations
https://doi.org/10.1016/s0168-8278(24)01331-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat